Jim Cramer Reacts to Mylan's Multiple Sclerosis Drug
Mylan scored FDA approval for a generic version of Teva Pharmaceuticals' multiple sclerosis drug, Copaxone.
Mylan (MYL) - Get Report scored FDA approval for a generic version of Teva Pharmaceuticals' (TEVA) - Get Report multiple sclerosis drug, Copaxone.
TheStreet's founder and Action Alerts PLUS Portfolio Manager Jim Cramer said this drug was one people thought Teva Pharmaceuticals would lose exclusivity to.
"We note, the ongoing challenges to its generics business and that with FDA approval of Mylan's generic of Copaxone, earnings/cash flow are likely to [be] affected" with the announcement, wrote David Steinberg of Jefferies in a morning note.
Watch all of Jim Cramer's latest videos, right here:
- Jim Cramer: I'm Concerned About the Federal Reserve's Balance Sheet
- Jim Cramer Reacts to Pepsico's Earnings
- Netflix's Original Programming Is Resonating Globally, Jim Cramer Says
- Jim Cramer Reveals One Characteristic About Tesla's Stock
